DEANNE RENDOCK: Open Payments
NPI 1831294321 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,946 in 206 payments from 19 companies in 2025. Trend: 2023 $2,749 · 2024 $3,238 · 2025 $3,946
Food & beverage: $3,929Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 70 | $1,146 |
| AstraZeneca Pharmaceuticals LP | 30 | $814 |
| Regeneron Healthcare Solutions, Inc. | 22 | $376 |
| Verona Pharma, Inc. | 14 | $270 |
| Viatris Specialty LLC | 14 | $219 |
| Insmed, Inc. | 10 | $163 |
| Amgen Inc. | 9 | $155 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $132 |
| GENZYME CORPORATION | 4 | $109 |
Products named: NUCALA, DUPIXENT, TEZSPIRE, TRELEGY ELLIPTA, FASENRA, Ohtuvayre, YUPELRI, AIRSUPRA.
Industry payments across CT — which companies pay providers there.
